Angela Alexander-Bryant
Overview
Explore the profile of Angela Alexander-Bryant including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
83
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Eckert T, Zobaer M, Boulos J, Alexander-Bryant A, Baker T, Rivers C, et al.
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941829
Background: Glioblastoma (GBM) is the most common primary malignant brain tumor, with fewer than 5% of patients surviving five years after diagnosis. The introduction of immune checkpoint inhibitors (ICIs), followed...
2.
Attia M, Ogunnaike E, Pitz M, Elbaz N, Panda D, Alexander-Bryant A, et al.
Biomater Sci
. 2023 Dec;
12(3):725-737.
PMID: 38099834
Drug delivery systems based on amphiphilic supramolecular macrocycles have garnered increased attention over the past two decades due to their ability to successfully formulate nanoparticles. Macrocyclic (MC) materials can self-assemble...
3.
Attia M, Ogunnaike E, Pitz M, Elbaz N, Panda D, Alexander-Bryant A, et al.
bioRxiv
. 2023 Dec;
PMID: 38045274
Graphical Abstract:
4.
Alatise K, Gardner S, Alexander-Bryant A
Cancers (Basel)
. 2022 Dec;
14(24).
PMID: 36551731
In the United States, over 100,000 women are diagnosed with a gynecologic malignancy every year, with ovarian cancer being the most lethal. One of the hallmark characteristics of ovarian cancer...
5.
Samec T, Alatise K, Boulos J, Gilmore S, Hazelton A, Coffin C, et al.
Mol Ther Nucleic Acids
. 2022 Oct;
30:95-111.
PMID: 36213692
Ovarian cancer has shown little improvement in survival among advanced-stage patients over the past decade. Current treatment strategies have been largely unsuccessful in treating advanced disease, with many patients experiencing...
6.
Pitz M, Elpers M, Nukovic A, Wilde S, Gregory A, Alexander-Bryant A
Biomedicines
. 2022 Sep;
10(9).
PMID: 36140265
Glioblastoma multiforme (GBM) is the most aggressive central nervous system tumor, and standard treatment, including surgical resection, radiation, and chemotherapy, has not significantly improved patient outcomes over the last 20...
7.
Samec T, Boulos J, Gilmore S, Hazelton A, Alexander-Bryant A
Mater Today Bio
. 2022 Apr;
14:100248.
PMID: 35434595
Current delivery strategies for cancer therapeutics commonly cause significant systemic side effects due to required high doses of therapeutic, inefficient cellular uptake of drug, and poor cell selectivity. Peptide-based delivery...
8.
Attia M, Montaser A, Arifuzzaman M, Pitz M, Jlassi K, Alexander-Bryant A, et al.
Polymers (Basel)
. 2021 Jul;
13(11).
PMID: 34205186
In this study we developed electrospun cellulose acetate nanofibers (CANFs) that were loaded with a model non-steroidal anti-inflammatory drug (NSAID) (ibuprofen, Ib) and coated with poly(acrylamide) (poly-AAm) hydrogel polymer using...
9.
Mbiki S, McClendon J, Alexander-Bryant A, Gilmore J
Med Biol Eng Comput
. 2020 Apr;
58(7):1419-1430.
PMID: 32314170
In cell-based research, the process of visually monitoring cells generates large image datasets that need to be evaluated for quantifiable information in order to track the effectiveness of treatments in...
10.
Iqbal S, Blenner M, Alexander-Bryant A, Larsen J
Biomacromolecules
. 2020 Feb;
21(4):1327-1350.
PMID: 32078290
Macromolecule-based therapeutic agents, particularly proteins, antigens, monoclonal antibodies, transcription factors, nucleic acids, and gene editing enzymes, have the potential to offer cures for previously untreatable diseases. However, they present an...